PNC Financial Services Group Inc. Decreases Stake in Humana Inc. $HUM
PNC Financial Services Group Inc. reduced its stake in Humana Inc. by 16.5% during the fourth quarter, selling 13,098 shares and ending with 66,125 shares valued at approximately $16.9 million. This move comes despite Humana reporting better-than-expected quarterly results with EPS of $10.31 and revenue of $39.65 billion, a 23.5% year-over-year increase. Analyst sentiment remains cautious, with the stock holding a "Hold" consensus rating and an average price target of $263.35.
Pzena Investment Management LLC Purchases 41,125 Shares of Humana Inc. $HUM
Pzena Investment Management LLC increased its stake in Humana Inc. by 1.0% in the fourth quarter, purchasing 41,125 shares and bringing its total holdings to over 4 million shares valued at $1.04 billion. Institutional investors and hedge funds own 92.38% of Humana, which recently reported better-than-expected quarterly earnings and revenue. Analysts currently maintain a "Hold" rating on the stock with a consensus target price of $260.83.
What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
A Sun Life U.S. report analyzing over 70,000 high-dollar medical claims reveals that secondary (comorbid) conditions, long inpatient hospitalizations, and injectable drugs are the primary drivers of medical claims exceeding $3 million. The report identifies orthopedic/musculoskeletal conditions, premature births, and cancer as common and costly conditions, with GLP-1s showing promise in reducing risks associated with high-dollar claims despite increased use. Sun Life emphasizes a whole-person care approach and offers various health support solutions to manage these rising healthcare costs.
Newport Trust Company LLC Decreases Position in Humana Inc. $HUM
Newport Trust Company LLC reduced its stake in Humana Inc. by 7.6% in the fourth quarter, selling 80,796 shares but still holding 985,738 shares valued at $252.5 million. This makes Humana the 26th largest position in their portfolio, representing 0.6% of their total holdings. Humana reported strong quarterly results with EPS of $10.31 and revenue of $39.65 billion, exceeding analyst expectations, and announced a quarterly dividend of $0.885 per share.
UnitedHealth Group (UNH) – Among the 10 High Quality Stocks to Buy According to Hedge Funds
UnitedHealth Group (UNH) is listed among the top 10 high-quality stocks favored by hedge funds. Analysts from UBS and BofA recently raised their price targets on UNH, citing strong Q1 results, improved Medicare Advantage rates, and confidence in margin recovery despite ongoing cost pressures from specialty drugs and behavioral health. The company, a major healthcare and well-being provider, encompasses Optum and UnitedHealthcare segments, demonstrating a bullish outlook from its leadership.
SBB, Humana to Divest Swedish Elderly Care Property for SEK237 Million
SBB and Humana have agreed to divest a Swedish elderly care property for SEK 237 million. This transaction will see the property sold to a company within Humana's group. SBB will continue to own a significant portion of the property, maintaining majority interest through their joint venture.
Glenview Capital sells 3.75M CVS shares, keeps it a top-3 holding
Glenview Capital has rebalanced its investment in CVS Health, selling 3.75 million shares after an 80% total return since May 2024. Despite this reduction for diversification, CVS remains one of Glenview's top three holdings, and the firm expresses strong confidence in its near, medium, and long-term outlook. The rebalancing followed healthy Q1 results and increased annual guidance for CVS.
Third-party pixel use greatly increases healthcare data breach risk: study
A new study reveals that hospitals utilizing third-party tracking pixels are 46% more likely to experience a data breach. These pixels, common in other industries, raise significant HIPAA compliance and data privacy concerns in healthcare by transmitting sensitive patient information to external vendors. Researchers recommend that hospitals adopt homegrown, first-party tracking pixels to maintain control over data collection and mitigate the risk of unintended disclosures and security lapses.
Humana (HUM) is Rebounding to a Multi-Year Improvement in Margins and Returns
Eagle Capital Management, in its Q1 2026 investor letter, highlighted Humana Inc. (NYSE:HUM), an American insurance company, despite its stock having seen significant recent gains. The firm believes Humana, along with UnitedHealth Group, is moving towards a multi-year improvement in margins and returns following a downtrend in Medicare Advantage, bolstered by cost-reduction efforts and AI implementation. Eagle Capital Management projects annual EPS growth exceeding 20% for Humana.
Agilon Health (AGL) Appoints Tim O’Rourke as Chief Executive Officer
Agilon Health (AGL) has appointed Tim O’Rourke as its new Chief Executive Officer and a member of the Board of Directors, effective May 7, 2026. This appointment follows a comprehensive search and marks a new growth phase for the company after a period of operational and financial transformation. O'Rourke brings over 25 years of healthcare leadership experience, including significant roles at Humana and as CEO of Ascension Complete, making him well-suited to drive Agilon Health's continued success in value-based care.
Agilon Health (AGL) Appoints Tim O’Rourke as Chief Executive Officer
Agilon Health (AGL) announced the appointment of Tim O’Rourke as Chief Executive Officer and a member of the Board of Directors, effective May 7, succeeding Ronald A. Williams. O’Rourke brings over 25 years of healthcare leadership experience from organizations like Help at Home and Humana, making him well-suited to lead Agilon Health in its next growth phase. The company partners with physician groups and health systems to support a value-based care model for senior patients.
CVS Health Stock Rallies 24% in a Month as Business Turnback Fuels Rebound
CVS Health Corp. (NYSE: CVS) has seen its shares jump 24% in the past month, driven by strong Q1 earnings, a turnaround in its insurance business, and positive analyst upgrades. The company reported better-than-expected revenue and EPS, leading to raised full-year guidance and highlighting improved business fundamentals across all three segments. Despite a notable debt load, analysts believe CVS is poised for further valuation increases due to its integrated healthcare model and attractive dividend yield, making it a compelling long-term investment.
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders
Humana (HUM) recently expanded its Medicare Advantage coverage for CVRx Inc.'s Barostim therapy, effective May 1, 2026, benefiting approximately 5.2 million Medicare Advantage members with eligible heart failure. This move aligns with Humana's strategy to enhance clinical quality and control costs, though regulatory shifts and existing financial uncertainties for Humana still warrant careful investor consideration. The decision is seen as supportive of advanced heart failure care, impacting Humana's investment narrative within the broader context of its financial forecasts and market valuation.
Private payer rates outpaced Medicare's by 47%: KFF
A new KFF analysis reveals that private payer rates for hospital care increased 47% faster than Medicare rates between April 2019 and April 2026, with private payer prices rising 30% compared to Medicare's 21%. This widening gap is attributed to factors like hospital consolidation and shifts in bargaining power. Lawmakers and policymakers are scrutinizing hospitals over rising costs, proposing measures like stronger antitrust enforcement and price transparency, while hospitals argue that increasing costs of care and insufficient Medicare reimbursement justify their pricing.
Humana Inc. stock underperforms Wednesday when compared to competitors
Humana Inc. (HUM) shares fell 2.08% to $304.10 on Wednesday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average rise significantly. This decline ended a three-day winning streak for Humana stock.
Humana Just Got a Massive Upgrade From Deutsche Bank: Price Target Nearly Doubles to $441
Deutsche Bank has aggressively upgraded Humana (NYSE:HUM) to Buy, nearly doubling its price target to $441 from $235, signaling a fundamental reset and recovery for the managed care company. This upgrade, along with Mizuho's price target raise, is driven by expectations of improved Medicare star ratings and a stabilizing managed care market, despite the stock's recent sharp rally and some ongoing risks. The bank views 2026 as an earnings bottom and a re-basing year, with October's star ratings serving as a key catalyst.
Low digital health literacy hamstrings seniors' health IT use
A report from CVS Health reveals that low digital health literacy significantly impacts seniors, preventing 58% of Medicare enrollees aged 65 and older from fully managing their health. Despite this, 86% of seniors are open to using health IT, highlighting a crucial opportunity for healthcare organizations to implement human-led educational programs. The findings challenge the assumption that older adults are resistant to technology, emphasizing the need for accessible resources to bridge the digital health literacy gap.
UnitedHealth Group Incorporated stock (US91324P1021): Q1 numbers, Medicare pressure and what’s nex
UnitedHealth Group (UNH) remains a focused healthcare stock due to its latest quarterly report and the ongoing impact of the Change Healthcare cyberattack. The company reported revenue growth but also higher medical cost trends in Q1 2026. This article explores UnitedHealth’s business model, key revenue drivers, industry trends, and competitive position, highlighting its importance for US investors despite regulatory and operational challenges.
Deutsche Bank Upgrades Humana to Buy From Hold, Adjusts PT to $441 From $235
Deutsche Bank has upgraded Humana (HUM) to a "Buy" rating from "Hold" and significantly increased its price target to $441 from $235. This positive adjustment reflects a strong vote of confidence in the managed healthcare company. Concurrently, Mizuho also adjusted its price target for Humana to $335 from $290, maintaining an "Outperform" rating, indicating a generally optimistic outlook from analysts.
Mitsubishi UFJ Asset Management UK Ltd. Sells 12,000 Shares of CVS Health Corporation $CVS
Mitsubishi UFJ Asset Management UK Ltd. significantly reduced its stake in CVS Health Corporation by 75% in Q4, selling 12,000 shares and retaining 4,000 shares valued at $317,000. Despite this sell-off, CVS Health reported strong quarterly results, beating EPS and revenue estimates, and reaffirmed its FY 2026 EPS guidance. Analysts generally maintain a "Moderate Buy" rating for CVS, with several firms raising price targets.
With Strong Cash Flow, GE HealthCare Technologies Stock Poised to Rise?
GE HealthCare Technologies (GEHC) presents a compelling investment opportunity due to its strong cash flow yield of 5.4%, robust operating margin of 12.6%, and a discounted valuation against its 2-year and 1-month highs. Despite facing low revenue growth, the company's fundamentals appear solid when compared to S&P medians. However, investors are cautioned to consider the inherent risks of single stock trades and market volatility, with alternatives and portfolio diversification strategies suggested by Trefis.
ChartWatch ASX Scans: Telstra, Suncorp, Life360, ARB Corp, Catapult Sports, Sonic Healthcare, Global X Cybersecurity ETF
This article provides a daily technical analysis of ASX stocks, identifying companies showing strong uptrends and downtrends based on Carl Capolingua's trend following methodology. It lists specific stocks like Telstra, Suncorp, and Global X Cybersecurity ETF in uptrends, and Life360, ARB Corp., and Sonic Healthcare in downtrends, along with key considerations for using these scan lists for investment research. Readers are encouraged to use these lists as an aid, not as a recommendation, and to conduct their own due diligence.
Universal Technical Institute Stock To $25?
Universal Technical Institute (UTI) stock has recently dropped by 13.1% in less than a month, from $41.50 to $36.08. Trefis maintains an "Unattractive" opinion on the stock and suggests it could fall further, possibly to $25, citing historical price levels and the potential for a deeper correction. Although historical data shows a median 12-month return of 8.2% after sharp dips, investors are advised against timing the bottom and instead to consider strategies like the Trefis High Quality Portfolio for consistent returns.
North Dakota State Investment Board Makes New $1.52 Million Investment in Humana Inc. $HUM
The North Dakota State Investment Board has initiated a new position in Humana Inc. (NYSE:HUM) by acquiring 5,922 shares valued at approximately $1.52 million during the fourth quarter. This move highlights ongoing institutional interest in Humana, with other hedge funds also increasing their holdings. Analysts currently rate Humana as a "Hold" with an average price target of $249.91, despite some recent target increases.
Moratorium unlikely to hurt Addus’ M and A efforts, CEO Allison says
Dirk Allison, CEO of Addus HomeCare, stated that a new six-month Medicare enrollment moratorium for hospices and home care agencies is unlikely to affect Addus's operations or its merger and acquisition strategy. This is primarily because personal care services, which constitute the majority of Addus's business, are exempt from the moratorium. Allison also believes the government's crackdown on fraud might benefit large, compliant providers like Addus, potentially encouraging smaller agencies to sell.
Berkshire Exit Puts Spotlight On UnitedHealth Earnings Strength And Regulatory Risks
Berkshire Hathaway has fully exited its stake in UnitedHealth Group (NYSE:UNH) after less than a year, prompting investors to re-evaluate the company's risk profile, particularly concerning regulatory scrutiny and cost pressures. While some see this as a red flag, other large institutions and analysts remain positive, citing UnitedHealth's scale and efficiency efforts. This exit amplifies attention on potential downside risks despite recent strong earnings and raised guidance.
Humana completes $1.5 billion pre-capitalized trust securities offering
Humana Inc. successfully issued and sold $1.5 billion in Pre-Capitalized Trust Securities through two separate trusts on May 15, 2026. This arrangement grants Humana on-demand access to capital, allowing it to issue senior notes to these trusts over specified periods. The trusts invested the proceeds in U.S. Treasury securities, and the P-Caps are mandatorily redeemable in 2036 and 2055 respectively.
Humana (HUM) creates Horseshoe trust structure for long-dated senior note funding
Humana Inc. has established a complex financing structure using two special-purpose trusts, Horseshoe Funding Trust I and II, which issued Pre-Capitalized Trust Securities (P-Caps). This arrangement provides Humana with the right to issue up to $750 million in 6.062% Senior Notes due 2036 and up to $750 million in 6.887% Senior Notes due 2055, creating long-dated funding capacity without immediately adding debt to its balance sheet. Humana will pay semi-annual facility fees on the unused portions of these issuance rights, which can be automatically or mandatorily exercised under certain conditions, including financial stress events or a decline in consolidated net worth below $4.0 billion.
Mohawk Industries stock hits 52-week low at $93.14 By Investing.com
Mohawk Industries (MHK) stock reached a new 52-week low of $93.14 amidst a year-to-date decline of 11.4%. Despite analysts revising earnings downwards for the upcoming period, the company remains profitable, and InvestingPro analysis suggests the stock is undervalued. This follows a strong Q1 2026 earnings report where EPS exceeded expectations, though revenue slightly missed projections, and Truist Securities adjusted its price target downwards due to lower Q2 guidance.
Here's Why Investors Should Stay Neutral on Humana Stock for Now
Humana Inc. (HUM) is positioned for growth due to increasing premiums, strategic acquisitions, an expanding value-based care platform, and an aging U.S. population, leading to a Zacks Rank #3 (Hold). Despite these strengths, the company faces challenges such as rising medical costs, increasing operating expenses, and a high debt-to-capital ratio. Investors are advised to maintain a neutral stance while monitoring these factors, though other medical stocks like BrightSpring Health Services, Globus Medical, and Electromed are rated Strong Buy.
Humana Inc stock (US4456581077): lawsuit over Medicare claims data adds pressure around managed-care
Humana Inc. is facing increased scrutiny as a federal judge allowed parts of a securities fraud lawsuit against the company to proceed, relating to alleged misstatements on Medicare Advantage utilization. This legal challenge, combined with rising medical costs and an evolving regulatory environment, is adding pressure to Humana's managed-care business outlook. Investors are closely monitoring the company's financial performance, particularly its medical loss ratio, and potential impacts from policy changes and regulatory audits.
GoHealth (NASDAQ: GOCO) posts steep Q1 2026 revenue drop and flags going‑concern risk
GoHealth (NASDAQ: GOCO) reported a significant revenue decline and widened net loss in Q1 2026, leading its management to express substantial doubt about the company's ability to continue as a going concern. The company's net revenues plummeted to $11.9 million from $221.0 million year-over-year, largely due to a strategic pullback in Medicare Advantage activities and high operating costs and debt interest. GoHealth is actively discussing strategic alternatives, including potential restructuring or a change of control, with its lenders to address liquidity issues and upcoming financial covenants.
Sportradar Securities Fraud Class Action Result of Compliance Misrepresentations and 22% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against Sportradar Group AG (NasdaqGS: SRAD) for investors who purchased shares between November 7, 2024, and April 21, 2026. The lawsuit alleges that Sportradar made false and misleading statements, including working with black-market gambling operators despite claiming strict legal compliance. Investors with substantial losses are encouraged to contact KSF and must file lead plaintiff applications by July 17, 2026.
JPMorgan (JPM) launches Humana-linked auto-call notes offering ≥15% annual contingent yield
JPMorgan Chase Financial Company LLC is offering Auto Callable Contingent Interest Notes linked to Humana Inc. common stock, expected to price around May 20, 2026, and settle around May 26, 2026. These notes offer a contingent quarterly interest rate of at least 15.00% per annum if Humana's stock price on review dates is at or above 55.00% of its initial value, and feature an automatic call if the stock price is at or above the initial value on specific review dates, with the earliest automatic call date being February 22, 2027. Investors face principal risk if the notes are not automatically called and the final value falls below a trigger value, potentially leading to losses of more than 45.00% of their principal.
Humana Just Ripped 48% in a Month. Is It Outperforming Other Healthcare Stocks Like UnitedHealth and Cigna?
Humana (HUM) stock has surged 48% in the past month, outperforming UnitedHealth Group (UNH) and Cigna Group (CI), largely due to favorable Medicare Advantage rates and strong Q1 2026 results. Humana's concentrated exposure to Medicare Advantage has allowed it to benefit more significantly from recent regulatory tailwinds. While analysts have raised price targets for Humana, some suggest the stock may be overvalued, noting that the recent rally could be a recovery from a multi-year drawdown rather than the start of a new bull market.
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx stock rose after Humana announced Medicare Advantage coverage for its Barostim therapy, effective May 1, 2026. This policy expands patient access to the heart failure treatment and covers both FDA-approved indications and patients in the BENEFIT-HF trial. The news follows other favorable reimbursement developments earlier in 2026 and is expected to strengthen CVRx's commercial position and drive future revenue growth in the neuromodulation devices market.
Helping seniors navigate digital-first health care
As digital-first health care becomes more common, many older adults struggle with digital health literacy, impacting their ability to manage health tasks. Research shows over 7 in 10 Medicare members feel confusion navigating online health information, underscoring the need for tailored digital experiences and support. CVS Health is addressing this by designing simpler digital tools, offering conversational AI navigation, and providing in-person support and classes to improve accessibility and trust for seniors.
Humana Inc stock (US4456581077): Medicare Advantage focus after latest earnings update
Humana Inc. remains a key player in the US Medicare Advantage market, with its recent Q1 2025 earnings and updated 2025 guidance highlighting the company's reliance on this volatile sector. The report, summarized from Humana's investor relations and Reuters, underscores ongoing challenges such as rising medical utilization costs balanced against premium revenue growth from an aging US population. Investors are urged to focus on margins, enrollment trends, and regulatory risks, as these largely dictate Humana's financial outcomes given its specialized business model.
Northwestern Mutual Wealth Management Co. Buys 321,277 Shares of Humana Inc. $HUM
Northwestern Mutual Wealth Management Co. significantly increased its stake in Humana Inc. (NYSE:HUM) by 10,277.6% in the fourth quarter, purchasing an additional 321,277 shares. This brings their total holdings to 324,403 shares, valued at $92,045,000, representing 0.27% of Humana. The article also details other institutional investor activity, updated analyst price targets, and recent financial performance for Humana.
Leeward Investments LLC MA Has $8.41 Million Position in Humana Inc. $HUM
Leeward Investments LLC MA increased its stake in Humana Inc. by 15.5% in the fourth quarter, bringing its total holdings to $8.41 million. Despite mixed analyst sentiment and some lowered earnings estimates, Humana recently beat quarterly earnings and revenue estimates and announced a quarterly dividend of $0.885 per share. The stock currently holds a "Hold" consensus rating with a target price of $249.91.
Glenview Capital Management Increases Stake in Humana (HUM)
Glenview Capital Management has increased its stake in Humana (HUM) as part of its Q1 portfolio expansion, indicating a strategic bet on the healthcare sector's growing demand. Humana, a major private health insurer focusing on government-sponsored programs, has a strong GF Score of 84/100, suggesting favorable long-term returns despite its premium P/E ratio of 32.62x. Insider buying activity also signals confidence in the company's future performance.
Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM
Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Humana Inc. (NYSE: HUM) regarding potential breaches of fiduciary duties by its officers and directors. This follows Humana's disclosure of higher-than-expected benefits expense ratios and significantly lower adjusted EPS for 2023 and 2024, which led to a securities class action lawsuit, partially allowed by the court to proceed. KSF encourages long-term Humana shareholders with relevant information to contact them.
Glenview adds Humana, exits Expedia, reduces Teva among Q1 trades (HUM:NYSE)
Glenview Capital Management made several significant portfolio adjustments in the first quarter, according to its latest 13F filing. The hedge fund notably added new positions in Humana, Cisco, Baker Hughes, Akamai, and Intel, while completely exiting its investments in Expedia and Knight-Swift. Additionally, Glenview reduced its holdings in Teva Pharmaceutical Industries.
Humana (NYSE:HUM) Upgraded by Zacks Research to Hold Rating
Zacks Research has upgraded Humana (NYSE:HUM) from a "strong sell" to a "hold" rating, despite trimming several of its earnings estimates for the company. This upgrade comes amidst mixed analyst opinions, with several firms raising price targets, leading to an average "Hold" rating and a target price of $246.83. Humana recently exceeded quarterly expectations, reporting $10.31 EPS on $39.65 billion in revenue, and its shares opened at $300.52, near its 52-week high.
Morgan Stanley Adjusts Price Target on Humana to $217 From $146, Maintains Underweight Rating
Morgan Stanley has increased its price target for Humana (HUM) to $217 from $146, while maintaining an Underweight rating on the stock. This adjustment comes amidst other analyst recommendations for Humana, with various firms setting new price targets. The article also provides a brief company profile for Humana Inc., outlining its business segments and financial data.
Humana Stock Outlook: Is Wall Street Bullish or Bearish?
Humana Inc. (HUM) has outperformed the S&P 500 and the iShares U.S. Healthcare Providers ETF over the past year and year-to-date. The company recently reported strong Q1 results, surpassing Wall Street's EPS and revenue expectations. However, despite this strong performance, analyst ratings lean more bearish than a month ago, with a consensus "Hold" rating, and shares are currently trading above the mean analyst target.
CVRx rebounds as Humana issues Medicare policy for Barostim
CVRx shares significantly increased after Humana, a major Medicare Advantage payer, issued a positive coverage policy for the company's Barostim therapy. This policy makes CVRx's Barostim available to Humana's 5.5 million Medicare Advantage members for heart failure treatment. The news is seen as a key step towards broader market adoption and increasing access for patients.
Humana Inc. Stock 12‑Month Price Target Raised to $246.46, Implies 18% Downside
Humana Inc.'s average price target has been increased to $246.46 by 24 analysts, with forecasts ranging from $180 to $290 per share. This updated target suggests an 18% potential downside based on the May 14 closing price. The consensus rating for Humana remains "Hold" among 29 analysts.
Humana Stock Outlook: Is Wall Street Bullish or Bearish?
Humana Inc. (HUM) has outperformed the broader market and the iShares U.S. Healthcare Providers ETF (IHF) over the past year and year-to-date, fueled by strong Q1 2026 results. Despite this performance, analyst consensus leans towards a "Hold" rating, with a recent shift towards a more bearish stance compared to a month ago. Analysts expect a significant decline in EPS for the current fiscal year.
FTI Consulting Survey: Majority of U.S. Hospital Leaders Predict Serious Financial Challenges in the Near Future
A new survey by FTI Consulting reveals that 92% of U.S. hospital leaders expect major financial challenges over the next decade due to affordability concerns, policy shifts, and care moving outside hospitals. The survey highlights interconnected pressures including physician recruitment constraints, data security concerns, and workforce shortages. Despite digital advancements, increased patient wait times persist, and while AI concerns have moderated, cybersecurity and data privacy are now top technological worries for hospitals.
